Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell therapy consists of allogeneic, bone-marrow-derived mesenchymal stromal cells (MSCs) developed by The University of Queensland for the treatment of chronic lung allograft dysfunction (CLAD) in lung transplant recipients. MSCs are characterized by their immune privilege and potent immunosuppressive and tolerogenic properties, which are leveraged to mitigate the inflammatory processes and organ rejection associated with CLAD. The therapy is currently being evaluated in the Phase 2 ASSIST-CLAD trial, where it is administered intravenously to patients with new-onset CLAD to potentially stabilize or improve lung function by modulating the host immune response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bone-marrow derived mesenchymal stromal cells (The University of Queensland).